208 related articles for article (PubMed ID: 7655858)
1. A novel technique for preparing improved buffy coat platelet concentrates.
Mrowiec ZR; Oleksowicz L; Dutcher JP; De Leon-Fernandez M; Lalezari P; Puszkin EG
Blood Cells Mol Dis; 1995; 21(1):25-33. PubMed ID: 7655858
[TBL] [Abstract][Full Text] [Related]
2. Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: combined strategies for reducing platelet activation during storage.
Mrowiec ZR; Oleksowicz L; Zuckerman D; De Leon-Fernandez M; Khorshidi M; Dutcher JP; Puszkin EG
Transfusion; 1996 Jan; 36(1):5-10. PubMed ID: 8607153
[TBL] [Abstract][Full Text] [Related]
3. [Blood fractionation based on the extraction of the buffy-coat layer. Analysis of our results].
Algora M; Torres P; Rodríguez MA; de la Calle C; Biurrún M; Nieto S; Ruiz M; Alonso MV
Sangre (Barc); 1995 Apr; 40(2):91-6. PubMed ID: 7784953
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the quality of hemoderivatives obtained using a buffy-coat extraction system with a top-and-bottom technique (Optipress II)].
Hurtado C; Bonanad S; Soler MA; Mirabet V; Blasco I; Planelles MD; de Miguel A
Sangre (Barc); 1999 Oct; 44(5):319-26. PubMed ID: 10618907
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of buffy-coat-derived platelet concentrates stored in a synthetic medium.
Fijnheer R; Veldman HA; van den Eertwegh AJ; Gouwerok CW; Homburg CH; Boomgaard MN; de Korte D; Roos D
Vox Sang; 1991; 60(1):16-22. PubMed ID: 2053325
[TBL] [Abstract][Full Text] [Related]
6. Prevention of acquired defects in platelet function during blood processing.
Washitani Y; Irita Y; Yamamoto K; Shiraki H; Kiyokawa H; Maeda Y; Yoshinari M
Transfusion; 1988; 28(6):571-5. PubMed ID: 3194931
[TBL] [Abstract][Full Text] [Related]
7. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods.
Fijnheer R; Pietersz RN; de Korte D; Gouwerok CW; Dekker WJ; Reesink HW; Roos D
Transfusion; 1990 Sep; 30(7):634-8. PubMed ID: 2144922
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.
Plaza EM; Lozano ML; Guiu IS; Egea JM; Vicente V; De Terán LC; Rivera J
Blood Transfus; 2012 Oct; 10(4):480-9. PubMed ID: 22682335
[TBL] [Abstract][Full Text] [Related]
9. The 'cherry buffy-coat syndrome', a cause of decreased platelet yield in platelet concentrates obtained from buffy-coats.
Rebulla P; Smacchia C; Greppi N; Porretti L; Lopa R; Cernuschi M; Sirchia G
Vox Sang; 2001 Jan; 80(1):57-60. PubMed ID: 11339070
[TBL] [Abstract][Full Text] [Related]
10. In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools.
Turner CP; Sutherland J; Wadhwa M; Dilger P; Cardigan R
Vox Sang; 2005 Apr; 88(3):164-71. PubMed ID: 15787726
[TBL] [Abstract][Full Text] [Related]
11. Survival in vivo of platelets stored for 48 hours in the buffycoat at 4 degrees C compared to platelet rich plasma stored at 22 degrees C.
Pietersz RN; Loos JA; Reesink HW
Blut; 1987 Apr; 54(4):201-6. PubMed ID: 3828537
[TBL] [Abstract][Full Text] [Related]
12. [Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis].
Mastronardi R; Cleophax S; Begué S; Hurtado-Nedelec M; Gross S; Bocquet T; Djoudi R
Transfus Clin Biol; 2019 Sep; 26(3):164-170. PubMed ID: 31400933
[TBL] [Abstract][Full Text] [Related]
13. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
[TBL] [Abstract][Full Text] [Related]
14. Quality assessment of the preparation and storage of leukocyte-depleted pooled platelet concentrates.
Chen F; Dai X; Li A; Zheng Y; Hu W
Hematology; 2024 Dec; 29(1):2293492. PubMed ID: 38193467
[TBL] [Abstract][Full Text] [Related]
15. The evolution of platelet procoagulant activity of remnant platelets in stored platelet concentrates prepared by the platelet-rich plasma method and the buffy coat method.
Van der Planken MG; Vertessen F; Mortelmans E; Van Bockstaele D; Muylle L; Mertens G; Berneman ZN
Ann Hematol; 1999 Jan; 78(1):1-7. PubMed ID: 10037261
[TBL] [Abstract][Full Text] [Related]
16. Buffy coat and cell separator granulocyte concentrates. Comparison of cell content and in vitro granulocyte function.
Hughes A; Addison IE; Al-Hadithy H; Brozović B
Vox Sang; 1981; 41(1):1-5. PubMed ID: 7324437
[TBL] [Abstract][Full Text] [Related]
17. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
Ali SF
Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
[TBL] [Abstract][Full Text] [Related]
18. Influence of a 12-hour, 22 degrees C holding period for buffy coats on the preparation of platelet concentrates stored in plasma.
Boeri N; Saleun S; Pelissier E; Saleun JP; Aiach M; Rendu F
Transfusion; 1994 Oct; 34(10):881-6. PubMed ID: 7940660
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of platelet concentrates, prepared from pooled buffy coats, stored for 8 days after filtration.
Boomgaard MN; Joustra-Dijkhuis AM; Gouwerok CW; Steneker I; Reesink HW; Loos JA; Pietersz RN; de Korte D
Transfusion; 1994 Apr; 34(4):311-6. PubMed ID: 8178328
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
Johnson L; Loh YS; Kwok M; Marks DC
Transfus Med; 2013 Apr; 23(2):121-9. PubMed ID: 23480103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
